Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) EBT (2016 - 2025)

Cardiff Oncology's EBT history spans 15 years, with the latest figure at -$7.2 million for Q4 2025.

  • For Q4 2025, EBT rose 38.78% year-over-year to -$7.2 million; the TTM value through Dec 2025 reached -$45.9 million, down 1.02%, while the annual FY2025 figure was -$45.9 million, 1.02% down from the prior year.
  • EBT for Q4 2025 was -$7.2 million at Cardiff Oncology, up from -$11.3 million in the prior quarter.
  • Across five years, EBT topped out at -$5.4 million in Q1 2021 and bottomed at -$13.9 million in Q2 2025.
  • The 5-year median for EBT is -$10.2 million (2022), against an average of -$10.2 million.
  • The largest annual shift saw EBT tumbled 103.49% in 2022 before it skyrocketed 38.78% in 2025.
  • A 5-year view of EBT shows it stood at -$9.5 million in 2021, then grew by 1.41% to -$9.4 million in 2022, then increased by 0.72% to -$9.3 million in 2023, then dropped by 26.39% to -$11.8 million in 2024, then surged by 38.78% to -$7.2 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's EBT are -$7.2 million (Q4 2025), -$11.3 million (Q3 2025), and -$13.9 million (Q2 2025).